Studying drug resistance in lung cancer
- Researcher: Professor Michael Seckl
- Institution: Imperial College School of Medicine, London, England
- Award Amount: £156,217 for 3 years from January 2013
- Cancer Type: Lung Cancer
About 10% of patients with non-small cell lung cancer have a mutation in the gene that controls a protein called EGFR. Some drugs exist that work on this mutation, and these drugs are initially very effective in about 90% of these patients. Unfortunately the cancer quickly becomes resistant to the treatment, and it is therefore important to overcome this resistance to ensure that more people survive this disease.
In previous work, Professor Seckl and his team found that cancer cells that were resistant to one of these drugs had very low amounts of a protein called glutathione inside their cells, and when glutathione levels were raised in these cells, they were less resistant to the drug. Professor Seckl wants to study molecules that control glutathione levels in the cancer cells and determine how they relate to resistance to drugs that target EGFR mutations. These results will be used to test whether new drugs that raise glutathione levels can be used to stop drug resistance in pre-clinical models. The results should help us to overcome drug resistance in lung cancer patients with the EGFR mutations, and prolong their survival.
Showing: All projects
The Research That Is Happening Right Now
Explore current projects to see how far-reaching our research is from a global perspective.
See the difference our research projects make.
Our philosophy is very simple: if we believe a project can make a difference in the fight against cancer then we will award a grant to make it happen. We’re not interested in national borders or any kind of geographical bias, just the most promising proposals. And that’s the very reason we ask t...Read more
Life in the Lab
Supporters often ask us what type of projects their donations are funding. What does a typical day in the life of a cancer researcher look like? To answer these questions and give you an insight into the vital work your support helps us to fund, we've put together this short video....Read more